Prognostic and clinicopathological role of RACK1 for cancer patients: a systematic review and meta-analysis.

Humans Disease-Free Survival Neoplasm Proteins / genetics Neoplasms / diagnosis Prognosis Receptors for Activated C Kinase / genetics
Biomarker Cancers Clinicopathological characteristics Meta-analysis Prognosis RACK1

Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2023
Historique:
received: 21 04 2023
accepted: 18 07 2023
medline: 22 8 2023
pubmed: 21 8 2023
entrez: 21 8 2023
Statut: epublish

Résumé

The receptor for activated C kinase 1 (RACK1) expression is associated with clinicopathological characteristics and the prognosis of various cancers; however, the conclusions are controversial. As a result, this study aimed to explore the clinicopathological and prognostic values of RACK1 expression in patients with cancer. PubMed, Embase, Web of Science, Cochrane Library, and Scopus were comprehensively explored from their inception to April 20, 2023, for selecting studies on the clinicopathological and prognostic role of RACK1 in patients with cancer that met the criteria for inclusion in this review. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the prognosis-predictive value of RACK1 expression, while pooled odds ratios (ORs) and 95% CIs were used to evaluate the correlation between RACK1 expression and the clinicopathological characteristics of patients with cancer. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale. Twenty-two studies (13 on prognosis and 20 on clinicopathological characteristics) were included in this systematic review and meta-analysis. The findings indicated that high RACK1 expression was significantly associated with poor overall survival (HR = 1.62; 95% CI, 1.13-2.33; RACK1 may be a global predictive marker of poor prognosis in patients with cancer and unfavorable clinicopathological characteristics. However, further clinical studies are required to validate these findings.

Sections du résumé

Background
The receptor for activated C kinase 1 (RACK1) expression is associated with clinicopathological characteristics and the prognosis of various cancers; however, the conclusions are controversial. As a result, this study aimed to explore the clinicopathological and prognostic values of RACK1 expression in patients with cancer.
Methodology
PubMed, Embase, Web of Science, Cochrane Library, and Scopus were comprehensively explored from their inception to April 20, 2023, for selecting studies on the clinicopathological and prognostic role of RACK1 in patients with cancer that met the criteria for inclusion in this review. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the prognosis-predictive value of RACK1 expression, while pooled odds ratios (ORs) and 95% CIs were used to evaluate the correlation between RACK1 expression and the clinicopathological characteristics of patients with cancer. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale.
Results
Twenty-two studies (13 on prognosis and 20 on clinicopathological characteristics) were included in this systematic review and meta-analysis. The findings indicated that high RACK1 expression was significantly associated with poor overall survival (HR = 1.62; 95% CI, 1.13-2.33;
Conclusions
RACK1 may be a global predictive marker of poor prognosis in patients with cancer and unfavorable clinicopathological characteristics. However, further clinical studies are required to validate these findings.

Identifiants

DOI: 10.7717/peerj.15873 PMID: 37601269 PMC: PMC10434108
pubmed: 37601269
doi: 10.7717/peerj.15873
pii: 15873
pmc: PMC10434108
doi:

Substances chimiques

Neoplasm Proteins 0
RACK1 protein, human 0
Receptors for Activated C Kinase 0

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15873

Informations de copyright

©2023 Wang et al.

Déclaration de conflit d'intérêts

The authors declare there are no competing interests.

Références

Int J Oncol. 2016 Aug;49(2):539-48
pubmed: 27279145
Cancer Lett. 2019 May 28;450:144-154
pubmed: 30849478
Nature. 2022 Aug;608(7921):199-208
pubmed: 35859180
Ann Surg. 2021 Dec 1;274(6):e1187-e1195
pubmed: 31972643
Oral Oncol. 2018 Jan;76:22-26
pubmed: 29290282
PeerJ. 2016 Feb 16;3:e1499
pubmed: 27047702
Cancer Res. 2015 Sep 15;75(18):3832-41
pubmed: 26199092
Onco Targets Ther. 2019 Feb 01;12:1007-1020
pubmed: 30774385
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F565-F576
pubmed: 28100502
Cancer Biol Ther. 2015;16(4):528-40
pubmed: 25719728
Cell Death Differ. 2022 Apr;29(4):697-708
pubmed: 34611296
Cancer Sci. 2022 Nov;113(11):3838-3851
pubmed: 35912545
Mol Oncol. 2020 Apr;14(4):795-807
pubmed: 31997535
Cell. 2021 Apr 29;184(9):2487-2502.e13
pubmed: 33857424
Science. 2017 Jul 07;357(6346):55-60
pubmed: 28684519
Mol Cancer. 2020 May 4;19(1):82
pubmed: 32366257
Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G263-G274
pubmed: 29025732
Int J Oncol. 2014 Apr;44(4):1252-8
pubmed: 24481459
J Biol Chem. 2012 Mar 9;287(11):7845-58
pubmed: 22262830
Int J Cancer. 2010 Sep 1;127(5):1172-9
pubmed: 20020495
Theranostics. 2021 Jan 1;11(7):3150-3166
pubmed: 33537079
Cancer Lett. 2016 Oct 10;381(1):217-36
pubmed: 26742462
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Exp Mol Pathol. 2016 Oct;101(2):176-186
pubmed: 27498047
Cancer Cell. 2022 Aug 8;40(8):865-878.e6
pubmed: 35944502
Mol Biol Rep. 2014 May;41(5):3393-9
pubmed: 24504450
Int J Oncol. 2022 Jul;61(1):
pubmed: 35616137
Cancer Res. 2021 Jan 15;81(2):289-302
pubmed: 33203703
Eur J Cancer. 2009 Feb;45(3):490-6
pubmed: 19087901
Cancer Lett. 2020 Jan 28;469:287-300
pubmed: 31705928
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Lung Cancer. 2021 Aug;158:9-14
pubmed: 34090182
Int J Environ Res Public Health. 2016 Oct 18;13(10):
pubmed: 27763568
Oncol Lett. 2017 Oct;14(4):4784-4792
pubmed: 29085480
Ann Surg Oncol. 2013 Mar;20(3):1044-52
pubmed: 22592183
Am J Physiol Gastrointest Liver Physiol. 2018 Jan 1;314(1):G1-G13
pubmed: 28935684
J Transl Med. 2016 May 11;14(1):131
pubmed: 27170279
Cell Death Dis. 2018 Nov 19;9(12):1148
pubmed: 30451832
Oncogene. 2021 Feb;40(5):1027-1042
pubmed: 33323973
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cell Res. 2014 Mar;24(3):359-71
pubmed: 24323043
J Biol Chem. 1994 Aug 26;269(34):21395-8
pubmed: 8063768
J Cancer. 2020 Jan 1;11(4):795-803
pubmed: 31949482
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4661-4670
pubmed: 30765517
Gastroenterol Res Pract. 2019 Mar 10;2019:5625026
pubmed: 30962803
Lung Cancer. 2010 Jul;69(1):54-9
pubmed: 19892429
PeerJ. 2021 Aug 17;9:e11901
pubmed: 34458019
Int J Oral Sci. 2022 Feb 14;14(1):8
pubmed: 35153298
Mol Pharmacol. 2002 Dec;62(6):1261-73
pubmed: 12435793
Oncol Lett. 2018 Feb;15(2):2073-2078
pubmed: 29434907
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):839-43
pubmed: 8302854
Nat Metab. 2020 Apr;2(4):318-334
pubmed: 32691018

Auteurs

Qiuhao Wang (Q)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Sixin Jiang (S)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Yuqi Wu (Y)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

You Zhang (Y)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Mei Huang (M)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Yan Qiu (Y)

Laboratory of Pathology, Clinical Research Center for Breast, Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.

Xiaobo Luo (X)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic and clinicopathological role of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Prognostic and clinicopathological role of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Prognostic and clinicopathological role of...
questionsmedicales.fr › Tumeurs › Prognostic and clinicopathological role of...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic and clinicopathological role of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs de kinase-C activée › Prognostic and clinicopathological role of...